Tracers / [177Lu]Lu-6R-RedFol-1

[177Lu]Lu-6R-RedFol-1

Also written as [Lu-177]Lu-6R-RedFol-1
Radionuclide
Lu-177 t½ 9584.6 min
Modality
Therapy
Production route
—
Stage
Reported once
Syntheses indexed
2
Preclinical only, no clinical indication yet

What it is

Compound class
5-methyltetrahydrofolate (5-MTHF)-based albumin-binding folate radioconjugate
Target / mechanism
Folate receptor (FR) targeting PMID 33063250
Clinical application
Folate receptor-positive tumors (radionuclide therapy) PMID 33063250
Theranostic pair
—

Regulatory status

FDA
—
EMA (centralised)
—
Other approvals
—
Brand names
—

Clinical use

Typical injected activity
—
Uptake time
—

Reported in the literature. Not a dosing recommendation.

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
Manual synthesis———>99%6R-RedFol-133063250
2021 Eur J Nucl Med Mol Imaging
The radiolabeling of the folate conjugates with lutetium-177 ... was performed at pH ~ 4.5 using no-carrier-added lutetium-177
——————41887740
2026 J Nucl Med

Need this precursor?We can point you to suppliers for [177Lu]Lu-6R-RedFol-1, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 33063250. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 33063250: '6R-RedFol-1 and 6S-RedFol-1, based on 6R-5-MTHF and 6S-5-MTHF, respectively, were designed as structural equivalents to the previously developed albumin-binding DOTA-folate conjugate'.